Nutron Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Nutron Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gro…

1990-10-12 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
NP Nutron Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Nutron Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Nutron Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 88/100. Nutron Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 1990, operating in the Chemicals and Materials sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Nutron Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
65/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 65/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (15.00 cr) · 6 satisfied (26.94 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.1 48.0 cr
Others1 48.0 cr
Citibank N.A.1 48.0 cr
The Sangli Bank Limited1 48.0 cr
Bank Of Madura Ltd2 48.0 cr
Bank Of Madura Ltf1 48.0 cr
Compliance Score: 93/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RITESH RAMESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
PRAFUL RAMESH SHAH 01234567 Director 01/04/2018 6 yrs Approved
POPATLAL HANJARIMAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
JAYESH POPATLAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
RAMESH HANJARIMAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
MANISH BHURALAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
DINESH POPATLAL SHAH 01234567 Director 01/04/2018 6 yrs Approved
  • 7 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 75
Growth signals & trust indicators
Operating for 35+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence86/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment76/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 15.00 cr already registered.
  • Compliance record supports lending.
Investor view66/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
18 Jul 2022
Charge satisfied
Citi Bank N.A.
Charge satisfied
Citibank N.A.
30 Jan 2021
Charge created
Others - 15.00 cr
20 Jan 2020
Charge satisfied
The Sangli Bank Limited
Charge satisfied
Bank Of Madura Ltf
Charge satisfied
Bank Of Madura Ltd
24 Sep 2013
Director ceased
RITESH RAMESH SHAH
Director ceased
PRAFUL RAMESH SHAH
18 Oct 2012
Director appointed
RITESH RAMESH SHAH (Director)
Director appointed
PRAFUL RAMESH SHAH (Director)
15 Feb 2008
Charge created
Citi Bank N.A. - 22.50 cr
05 Mar 2007
Charge created
Citibank N.A. - 2.50 cr
17 Sep 2003
Charge created
The Sangli Bank Limited - 1.50 cr
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
7 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Movantis Mobilza Private Limited U74999DL2018PTC336291 New Delhi, Delhi, India
Jenirich Agro Products Private Limited U51909TN2010PTC076612 Tuticorin, Tamil Nadu, India
K L B Instruments Company Private Limited U74899DL1984PTC019015 Na, Delhi, India
Nissan Agro Tech India Private Limited U74999HR2017FTC070080 Gurgaon, Haryana, India
Raviraj Enterprises Private Limited U74999AP1989PTC010244 Na, Andhra Pradesh, India
Leadmark Wholesale Private Limited U51909KA2019FTC125268 Bangalore South, Karnataka, India
Yarncoms India Private Limited U51909TZ2012PTC018548 Coimbatore, Tamil Nadu, India
Mobiocean U72200DL2015PTC285802 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Nutron Pharmaceuticals Private Limited before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Nutron Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 65/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Nutron Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Nutron Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Nutron Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Nutron Pharmaceuticals Private Limited an active company?

Nutron Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 93/100 (Low Risk).

Is Nutron Pharmaceuticals Private Limited financially healthy?

Nutron Pharmaceuticals Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Nutron Pharmaceuticals Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Nutron Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 7 active director(s) are on record.

Does Nutron Pharmaceuticals Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 6 earlier charge(s) stand satisfied.

Is Nutron Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).

Is it risky to lend to Nutron Pharmaceuticals Private Limited?

Its Credit Risk Score is 65/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.